Isotechnika Pharma Inc IPHAF

another

[MAXUUM]

bject: ISOTECHNIKA CEO FEATURED ON AMERICAN BUSINESS TV SHOW HOSTED BY GENERAL ALEXANDER HAIG Date: Tue, 30 Oct 2001 16:14:10 -0700 From: [e-mail] To: [e-mail] Edmonton, Alberta, October 30th, 2001 - Isotechnika Inc., CEO, Dr. Robert Foster will be featured on a U.S. Business Show  the World Business Review Health Journal Television series hosted by General Alexander Haig. The episode will air October 30st through November 4th on U.S. public stations in markets that include New York, Chicago, San Francisco and Miami. The show reaches hundreds of Forbes 1000 type companies and is available to 75 million PC users for three months as video on demand (Yahoo) at Broadcast.coms Health and Fitness section. Up to 150,000 passengers aboard United Airlines Flights will have a chance to watch it along with the movies. For specific market-by-market airdates and times, please e-mail [e-mail] Isotechnika was chosen to be on the program due to its new drug alternative to Cyclosporine, ISATX247, said Wendy Altman, the shows coordinating producer. Dr. Foster says:  Our company is becoming widely known in Canada and this show gives us exposure to a large, new group of investors in the U.S. who may be looking for an opportunity to invest in a biotech company like ours. Health Journal Television is directed at a select American audience, via PBS, the Business and Technology Network. It airs directly to medical facilities, medical corporations, medical insurance companies and medical associations, as well as HSTN (Health & Science Television Network). OTHER MILESTONES ISOTECHNIKA ADDED TO THE TSE-300 Earlier this month Isotechnika was added to the TSE  300 Index. Dr. Foster says: Its further recognition of Isotechnikas growing role in the biotech field. ISOTECHNIKA UNVEILS NEW WEBSITE Also earlier this month Isotechnika unveiled a new, up-to-date website. The General Al Haig report on Dr. Foster and Isotechnika can be viewed on the website. ABOUT ISOTECHNIKA Isotechnika is a life-sciences company headquartered in Edmonton, Alberta, Canada. The company trades on the Toronto Stock Exchange under the symbol ISA. It is included in the TSE  300 composite index. The Companys lead drug is ISATX247; a novel platform designed to prevent organ rejection following transplantation as well as the treatment of autoimmune diseases. Isotechnika also globally markets and distributes its internally developed breath-test diagnostic product line. One of these products, the Helikit, is regarded as the gold standard for the diagnosis of ulcers. For Further information: Dr. Robert Foster Dr. Randall Yatscoff Chairman & CEO President & COO Isotechnika Inc. Isotechnika Inc. 780 487 1600 780 487 1600 780 484 4105 (fax) [e-mail] [e-mail] Mr. Joseph Koziak Executive Vice President Isotechnika Inc. 8585 East Hartford Drive Scottsdale, AZ 85255 480 505 0543